Protocol Ledger

NCT06112314 · Phase III · RECRUITING

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Interventional Phase III clinical trial protocol NCT06112314 sponsored by Immunocore in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-06-05 Enrollment: 680 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06112314
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)680 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06112314
Protocol FieldVerified Registry Value
NCT IdentifierNCT06112314
Consolidated Lead SponsorImmunocore
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment680 participants (ESTIMATED)
Registered Start Date2024-06-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI